Illumina has agreed to acquire SomaLogic from Standard BioTools for up to $425 million. The acquisition expands Illumina’s capabilities in proteomics and enhances its multiomics strategy by integrating SomaLogic’s DNA aptamer-based proteomic platforms. The two companies have collaborated since 2021, developing co-branded NGS-based proteomics products with commercial launch planned for late 2025. This move solidifies Illumina’s position in advanced biomarker discovery and disease profiling markets with over 250 SomaLogic employees and facilities included in the deal.